References
- Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, Adcock IM, Bateman ED, Bel EH, Bleecker ER, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–373. doi:https://doi.org/10.1183/09031936.00202013. PMID:24337046.
- Chen W, Safari A, FitzGerald JM, Sin DD, Tavakoli H, Sadatsafavi M. Economic burden of multimorbidity in patients with severe asthma: a 20-year population-based study. Thorax. 2019;74(12):1113–1119. doi:https://doi.org/10.1136/thoraxjnl-2019-213223. PMID:31534029.
- Bakakos A, Loukides S, Bakakos P. Severe eosinophilic asthma. J Clin Med. 2019;8(9):1375–1398. doi:https://doi.org/10.3390/jcm8091375. PMID:31480806.
- Humbert M, Beasley R, Ayres J, Slavin R, Hebert J, Bousquet J, Beeh KM, Ramos S, Canonica GW, Hedgecock S, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005;60(3):309–316. doi:https://doi.org/10.1111/j.1398-9995.2004.00772.x. PMID:15679715.
- Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, Sproule S, Gilmartin G, Aurivillius M, Werkstrom V, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2115–2127. PMID:27609408. doi:https://doi.org/10.1016/S0140-6736(16)31324-1.
- Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, Ortega H, Chanez P. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651–659. PMID:22901886. doi:https://doi.org/10.1016/S0140-6736(12)60988-X.
- Tian BP, Zhang GS, Lou J, Zhou HB, Cui W. Efficacy and safety of benralizumab for eosinophilic asthma: a systematic review and meta-analysis of randomized controlled trials. J Asthma. 2018;55(9):956–965. PMID:29211545. doi:https://doi.org/10.1080/02770903.2017.1379534.
- Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, Busse WW, Ford L, Sher L, FitzGerald JM, et al. dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486–2496. PMID:29782217. doi:https://doi.org/10.1056/NEJMoa1804092.
- Busse W, Chupp G, Nagase H, Albers FC, Doyle S, Shen Q, Bratton DJ, Gunsoy NB. Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison. J Allergy Clin Immunol. 2019;143(1):190–200.e20. PMID:30205189. doi:https://doi.org/10.1016/j.jaci.2018.08.031.
- Bourdin A, Husereau D, Molinari N, Golam S, Siddiqui MK, Lindner L, Xu X. Matching-adjusted indirect comparison of benralizumab versus interleukin-5 inhibitors for the treatment of severe asthma: a systematic review. Eur Respir J. 2018;52(5):1801393. PMID:30309978. doi:https://doi.org/10.1183/13993003.01393-2018.
- Ohta K, Nagase H, Suzukawa M, Ohta S. Antibody therapy for the management of severe asthma with eosinophilic inflammation. Int Immunol. 2017;29(7):337–343. doi:https://doi.org/10.1093/intimm/dxx045. PMID:28910970.
- Kolbeck R, Kozhich A, Koike M, Peng L, Andersson CK, Damschroder MM, Reed JL, Woods R, Dall’acqua WW, Stephens GL, et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol. 2010;125(6):1344–1353.e2. doi:https://doi.org/10.1016/j.jaci.2010.04.004. PMID:20513525.
- FitzGerald JM, Bleecker ER, Menzies-Gow A, Zangrilli JG, Hirsch I, Metcalfe P, Newbold P, Goldman M. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies. Lancet Respir Med. 2018;6(1):51–64. PMID:28919200. doi:https://doi.org/10.1016/S2213-2600(17)30344-2.
- FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, Ferguson GT, Busse WW, Barker P, Sproule S, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2128–2141. PMID:27609406. doi:https://doi.org/10.1016/S0140-6736(16)31322-8.
- Casale TB, Chipps BE, Rosen K, Trzaskoma B, Haselkorn T, Omachi TA, Greenberg S, Hanania NA. Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma. Allergy. 2018;73(2):490–497. PMID:28859263. doi:https://doi.org/10.1111/all.13302.
- Zierau L, Walsted ES, Thomsen SF, Backer V. Response to omalizumab in patients with severe allergic asthma: a real-life study. Respir Med. 2017;131:109–113. doi:https://doi.org/10.1016/j.rmed.2017.08.011. PMID:28947015.
- Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, Humbert M, Katz LE, Keene ON, Yancey SW, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198–1207. PMID:25199059. doi:https://doi.org/10.1056/NEJMoa1403290.
- Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P, Murphy K, Maspero JF, O’Brien C, Korn S. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3(5):355–366. PMID:25736990. doi:https://doi.org/10.1016/S2213-2600(15)00042-9.
- Hanania NA, Wenzel S, Rosen K, Hsieh HJ, Mosesova S, Choy DF, Lal P, Arron JR, Harris JM, Busse W. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013;187(8):804–811. doi:https://doi.org/10.1164/rccm.201208-1414OC. PMID:23471469.
- Tohda Y, Nakamura Y, Fujisawa T, Ebisawa M, Arima K, Miyata M, Takahashi Y, Rice MS, Deniz Y, Rowe P, et al. Dupilumab efficacy and safety in Japanese patients with uncontrolled, moderate-to-severe asthma in the phase 3 LIBERTY ASTHMA QUEST study. Allergol Int. 2020;69(4):578–587. doi:https://doi.org/10.1016/j.alit.2020.04.002. PMID:32444306.
- Suzukawa M, Matsumoto H, Ohshima N, Tashimo H, Asari I, Tajiri T, Niimi A, Nagase H, Matsui H, Kobayashi N, et al. Baseline serum CXCL10 and IL-12 levels may predict severe asthmatics’ responsiveness to omalizumab. Respir Med. 2018;134:95–102. doi:https://doi.org/10.1016/j.rmed.2017.12.002. PMID:29413515.
- Tajiri T, Matsumoto H, Gon Y, Ito R, Hashimoto S, Izuhara K, Suzukawa M, Ohta K, Ono J, Ohta S, et al. Utility of serum periostin and free IgE levels in evaluating responsiveness to omalizumab in patients with severe asthma. Allergy. 2016;71(10):1472–1479. doi:https://doi.org/10.1111/all.12922. PMID:27113353.
- Suzukawa M, Ohshima N, Tashimo H, Asari I, Kobayashi N, Shoji S, Tohma S, Ohta K. A low serum CCL4/MIP-1β level may predict a severe asthmatic responsiveness to mepolizumab. Intern Med. 2020;59(22):2849–2855. doi:https://doi.org/10.2169/internalmedicine.5159-20. PMID:32713920.
- Holguin F, Cardet JC, Chung KF, Diver S, Ferreira DS, Fitzpatrick A, Gaga M, Kellermeyer L, Khurana S, Knight S, et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2020;55(1):1900588. PMID:31558662. doi:https://doi.org/10.1183/13993003.00588-2019.
- Harrison TW, Chanez P, Menzella F, Canonica GW, Louis R, Cosio BG, Lugogo NL, Mohan A, Burden A, McDermott L, et al. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial. Lancet Respir Med. 2020;9(3):260–274. doi:https://doi.org/10.1016/S2213-2600(20)30414-8.PMID:33357499.
- Liu T, Wang F, Wang G, Mao H. Efficacy and safety of benralizumab in patients with eosinophilic asthma: a meta-analysis of randomized placebo-controlled trials. Front Med. 2018;12(3):340–349. doi:https://doi.org/10.1007/s11684-017-0565-0. PMID:29086236.
- Santanello NC, Zhang J, Seidenberg B, Reiss TF, Barber BL. What are minimal important changes for asthma measures in a clinical trial?Eur Respir J. 1999;14(1):23–7. doi:https://doi.org/10.1034/j.1399-3003.1999.14a06.x. PMID:10489824.
- Jackson DJ, Humbert M, Hirsch I, Newbold P, Garcia Gil E. Ability of serum IgE concentration to predict exacerbation risk and benralizumab efficacy for patients with severe eosinophilic asthma. Adv Ther. 2020;37(2):718–729. PMID:31836949. doi:https://doi.org/10.1007/s12325-019-01191-2.
- Castro M, Wenzel SE, Bleecker ER, Pizzichini E, Kuna P, Busse WW, Gossage DL, Ward CK, Wu Y, Wang B, et al. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med. 2014;2(11):879–890. PMID:25306557. doi:https://doi.org/10.1016/S2213-2600(14)70201-2.
- Chipps BE, Newbold P, Hirsch I, Trudo F, Goldman M. Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma. Ann Allergy Asthma Immunol. 2018;120(5):504–511 e4. PMID:29409951. doi:https://doi.org/10.1016/j.anai.2018.01.030.
- Rot A, Krieger M, Brunner T, Bischoff SC, Schall TJ, Dahinden CA. RANTES and macrophage inflammatory protein 1 alpha induce the migration and activation of normal human eosinophil granulocytes. J Exp Med. 1992;176(6):1489–1495. doi:https://doi.org/10.1084/jem.176.6.1489. PMID:1281207.
- Pham TH, Damera G, Newbold P, Ranade K. Reductions in eosinophil biomarkers by benralizumab in patients with asthma. Respir Med. 2016;111:21–29. PMID:26775606. doi:https://doi.org/10.1016/j.rmed.2016.01.003.
- Sridhar S, Liu H, Pham TH, Damera G, Newbold P. Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases. Respir Res. 2019;20(1):14–25. PMID:30658649. doi:https://doi.org/10.1186/s12931-018-0968-8.
- Stein ML, Villanueva JM, Buckmeier BK, Yamada Y, Filipovich AH, Assa’ad AH, Rothenberg ME. Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels. J Allergy Clin Immunol. 2008;121(6):1473–1483.e4. PMID:18410960. doi:https://doi.org/10.1016/j.jaci.2008.02.033.